Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT04993014
What this trial is testing

Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer

Who this might be right for
Breast NeoplasmsHER2-positive Breast CancerCirculating Tumor Cell
AC Camargo Cancer Center 80
Testing effectiveness (Phase 2)UnknownNCT02993198
What this trial is testing

A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging

Who this might be right for
HER2 Positive Breast CancerCardiovascular Abnormalities
Northwestern University 134
Large-scale testing (Phase 3)Active Not RecruitingNCT06144944
What this trial is testing

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

Who this might be right for
Breast Cancer InvasiveHormone-receptor-positive Breast CancerHER2 Low Breast Carcinoma+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 160
Large-scale testing (Phase 3)Looking for participantsNCT05827081
What this trial is testing

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Who this might be right for
Early Breast Cancer
Novartis Pharmaceuticals 1,400
Not applicableNot Yet RecruitingNCT06810492
What this trial is testing

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

Who this might be right for
Breast Cancer Stage IIIBreast Cancer Stage II
Hongmei Zheng, PhD 40
Not applicableStudy completedNCT06161922
What this trial is testing

Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy

Who this might be right for
HER2-positive Breast Cancer
Fudan University 600
Large-scale testing (Phase 3)Study completedNCT04629846
What this trial is testing

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Who this might be right for
Breast Cancer
Qilu Pharmaceutical Co., Ltd. 517
Testing effectiveness (Phase 2)Active Not RecruitingNCT04172259
What this trial is testing

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Who this might be right for
Breast CancerNeoadjuvant Chemotherapy
Sun Yat-sen University 156
Testing effectiveness (Phase 2)Looking for participantsNCT05292742
What this trial is testing

Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

Who this might be right for
Breast CancerAdjuvant Therapy
Fujian Medical University Union Hospital 206
Testing effectiveness (Phase 2)Study completedNCT02441946
What this trial is testing

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Breast CancerHormone Receptor Positive TumorEarly-Stage Breast Carcinoma
Eli Lilly and Company 224
Large-scale testing (Phase 3)Looking for participantsNCT05760612
What this trial is testing

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Who this might be right for
Early-stage Breast CancerHER2-positive Breast CancerAdjuvant Treatment After Trastuzumab+2 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Large-scale testing (Phase 3)Study completedNCT03493854
What this trial is testing

Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Who this might be right for
Early Breast Cancer
Hoffmann-La Roche 500
Post-approval studies (Phase 4)Not Yet RecruitingNCT07589699
What this trial is testing

Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP

Who this might be right for
Breast CancerHER2-positive Breast CancerEarly-stage Breast Cancer+1 more
The First Affiliated Hospital with Nanjing Medical University 59
Large-scale testing (Phase 3)Study completedNCT00615602
What this trial is testing

Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 489
Testing effectiveness (Phase 2)Active Not RecruitingNCT05558722
What this trial is testing

Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer

Who this might be right for
Breast Cancer Stage II
Xijing Hospital 31
Testing effectiveness (Phase 2)Ended earlyNCT05744375
What this trial is testing

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
Spanish Breast Cancer Research Group 2
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06548178
What this trial is testing

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Fudan University 242
Large-scale testing (Phase 3)Not Yet RecruitingNCT05388500
What this trial is testing

Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)

Who this might be right for
HER2-positive Breast Cancer
Institut de cancérologie Strasbourg Europe 800
Large-scale testing (Phase 3)UnknownNCT04665986
What this trial is testing

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 50
Large-scale testing (Phase 3)Study completedNCT02040935
What this trial is testing

SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants

Who this might be right for
Breast Cancer
Hoffmann-La Roche 128
Next Page